Digital Therapeutics: How Apps and Software Can Treat Medical Conditions

Digital therapeutics use software to deliver or support treatment for a medical condition. Unlike a general health app, a digital therapeutic is designed around a clinical purpose and should be evaluated for evidence, safety, and the specific regulatory status that applies to its product and intended use.

These tools may guide behavioral exercises, help people manage symptoms, or support care between appointments. They can expand access and make some treatment steps easier to practice, but they do not automatically replace a clinician, medication, or established care.

What are digital therapeutics?

Digital therapeutics (DTx) are software-based interventions intended to prevent, manage, or treat a medical condition. They use therapeutic methods, such as structured behavioral programs, and should be supported by evidence appropriate to their intended use.

A DTx may be a smartphone app, a web program, or software used with another device. Some products deliver treatment directly to a patient; others complement clinician-led care. For example, a program might teach a defined set of skills for managing a condition, then use a patient’s responses to tailor the next exercise.

The term is related to software as a medical device (SaMD), a regulatory concept for software that performs a medical purpose without being part of a physical medical device. The terms are not interchangeable in every context: DTx describes a therapeutic approach, while SaMD describes a category of medical software. Whether a specific product is regulated, and how, depends on its claims, intended use, and jurisdiction.

Prescription digital therapeutics (PDTs) are a subset designed to be prescribed or otherwise provided through a defined clinical pathway. A prescription does not, by itself, establish that every feature suits every patient. Product-specific evidence and instructions still matter.

How digital therapeutics work

Digital therapeutics work by delivering a structured intervention through software, often combining lessons, exercises, progress tracking, and feedback. Some involve a clinician; others are designed for patients to use independently within specified limits.

Programs may draw on established therapeutic techniques, such as cognitive behavioral strategies, skills practice, education, or habit support. An app can break a treatment plan into short activities, prompt regular practice, and record symptom reports or completion. That record may help a patient and clinician discuss patterns, though self-reported data is not the same as a diagnosis or clinical measurement.

Feedback can be simple, such as reminders and progress summaries, or adaptive, with later content responding to earlier answers. The value depends on how well the software’s design matches the intervention and the patient’s needs. Frequent notifications, for instance, may help one person build a routine and frustrate another.

Clinician involvement varies. A care team may recommend a product, review progress, and decide whether to adjust treatment. In other models, the software offers a guided program with limited professional contact. Before starting, patients should understand who monitors their information, what to do if symptoms worsen, and how the program fits with their other care.

Digital therapeutics vs. wellness apps and telehealth

The main difference is purpose: digital therapeutics aim to treat or manage a medical condition, wellness apps support general health habits, and telehealth connects patients with clinicians remotely. Their evidence requirements and oversight can differ substantially.

• Digital therapeutics: Designed for a defined clinical purpose, with product-specific evidence and potentially applicable medical-device regulation.
• Wellness apps: Often support goals such as sleep routines, fitness, or meditation without claiming to diagnose or treat a disease. A polished interface or health-related content does not make an app a medical treatment.
• Telehealth: Delivers clinical services, such as a video appointment or remote consultation. It may include a DTx in a care plan, but telehealth itself is a way to provide care, not necessarily a software treatment.

These categories can overlap in a broader digital care pathway. A clinician might use telehealth to assess a patient, recommend a DTx for between-visit practice, and suggest a wellness app for a separate lifestyle goal. The practical question is not whether an app looks medical; it is what the product claims to do, what evidence supports that claim, and what oversight applies.

Conditions digital therapeutics may address

Digital therapeutics may address selected conditions in areas such as behavioral health and chronic disease management, but each product is intended for a specific use and patient group. No single app should be assumed to treat every condition in a category.

In behavioral health, some programs provide structured exercises or skills practice for defined needs. Their intended role may be standalone support, an addition to therapy, or a tool used under professional guidance. Patients should check whether the program is meant for their age group and circumstances, and whether it gives clear advice for urgent symptoms or crisis situations.

For chronic disease management, software may support self-management through education, symptom or behavior tracking, and prompts to follow a care plan. It can make day-to-day routines more visible, but it cannot reliably replace clinical evaluation when symptoms change or complications arise. Some products may also complement medication or other established treatment; others have different intended roles.

When considering a specific DTx, look beyond the condition name. Check the product’s target population, the treatment goal, how long the program is designed to be used, and what outcomes were studied. Evidence for one product does not transfer automatically to another app, even if both address a similar condition.

Evidence, regulation, and safety

Evidence, regulatory status, privacy safeguards, and usability must be checked for each digital therapeutic. A product’s medical claims and intended use determine which regulatory requirements may apply; there is no blanket approval that covers all health apps.

Clinical validation asks whether the product has been evaluated for the outcomes it claims to improve and for the population it is intended to serve. Look for clear information about the study design, comparison group, duration, and measured outcomes. A study of an early version may not prove that a later version works the same way, especially if the treatment content or software changes.

Regulatory approval or clearance is also product- and jurisdiction-specific. In the United States, the FDA describes categories and oversight for certain medical device software; its digital health resources can help explain the landscape. Patients should verify a product’s status using official sources or a healthcare professional rather than relying only on advertising language such as “clinically proven.”

Safety includes more than treatment effects. Consider whether the app explains its limits, provides a route to human support, and tells users what to do if their condition worsens. Check its data privacy and security practices, including what information it collects, why it collects it, whether it shares data, and how users can delete an account. Convenience can come with a trade-off: detailed tracking may support personalization but also create more sensitive data to protect.

Using digital therapeutics in a care plan

To use a digital therapeutic safely, confirm that it fits the condition and treatment goal, check its evidence and access requirements, and agree with your care team on how to monitor progress. A DTx is most useful when its role in the wider care plan is clear.

1. Clarify the goal. Ask what the software is intended to change, and whether that goal matches your current care needs.
2. Check fit and access. Confirm eligibility, language, accessibility features, device and internet needs, cost, and whether a prescription or clinician referral is required.
3. Review the evidence and safeguards. Ask what studies support this exact product, what regulatory status applies, and how the provider handles personal data.
4. Plan follow-up. Decide how often to use it, what progress to track, and whom to contact if symptoms worsen or the program is difficult to use.

Clinicians can make integration more practical by explaining how the software relates to medication, therapy, or other treatment, and by setting a review point. Patients can bring questions or a progress summary to appointments, while remembering that app-generated scores may not be validated clinical measures.

Common pitfalls include treating a wellness app as a proven treatment, assuming regulatory status means a product will work for every individual, or stopping existing care because an app is available. Avoid these shortcuts: verify the product’s intended use, discuss changes with the treating professional, and report adverse effects or worsening symptoms. Digital therapeutics can add a useful treatment option, but the decision should rest on the patient’s needs and the evidence for that particular software.

Frequently asked questions

Are digital therapeutics the same as health and wellness apps? No. A DTx is intended to treat or manage a medical condition and should have evidence relevant to that use. Wellness apps generally support broader health habits and may not be clinically validated treatments.

Do digital therapeutics require a prescription? Some do, particularly prescription digital therapeutics; others may be accessed without one. Requirements depend on the product and local rules.

How can I tell whether a digital therapeutic is clinically validated? Look for product-specific studies, the population and outcomes studied, and a clear explanation of regulatory status. Ask a clinician or pharmacist if those details are unclear.

Can digital therapeutics replace medication or in-person care? Not automatically. A specific product may have a defined role in treatment, but patients should not stop medication, therapy, or follow-up without discussing the change with their healthcare professional.